Capital O2 Natural Health Company Ltd
⚠️ High Risk
FEI: 3013153905 • South Odorkor, Greater Accra • GHANA
FEI Number
3013153905
Location
South Odorkor, Greater Accra
Country
GHANAAddress
6 Carcass Road, South Odorkor, South Odorkor, Greater Accra, Ghana
High Risk
FDA Import Risk Assessment
This firm has a significant history of FDA import refusals with notable violations.
Statistics
Score Breakdown
How is this score calculated?
Proprietary Algorithm
- 40% Violation Severity — AI-assessed (1-10)
- 30% Refusal Volume — Logarithmic scale
- 20% Recency — Decays over 5 years
- 10% Frequency — Refusals per year
© ImportRefusal.com Original Analysis
Violation Summary
UNAPPROVED
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
DIRECTIONS
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it is a device whose label appears to not bear adequate directions for use.
NOT LISTED
It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).
LABELING
The article appears in violation of FPLA because of its placement, form and/or contents statement.
LIST INGRE
The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it appears to be misbranded within the meaning of Section 403(i)(2) of the FD&C Act in that it is fabricated from two or more ingredients and the label fails to bear the common or usual name of each such ingredient and/or the article purports to be a beverage containing vegetable or fruit juice, but does not bear a statement with appropriate prominence on the information panel of the total percentage of such fruit or vegetable juice contained in the food.
NUTRIT LBL
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be misbranded in that the label or labeling fails to bear the required nutrition information.
DIRSEXMPT
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.
LACKS N/C
The article is in package form and appears to not have a label containing an accurate statement of the quantity of the contents in terms of weight, measure or numerical count and no variations or exemptions have been prescribed by regs.
NCONTACT
The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it is a dietary supplement that appears to be misbranded within the meaning of Section 403(y) of the FD&C Act in that the dietary supplement label fails to bear a domestic address or phone number through which the responsible person (as described in section 761 of the FD&C Act) may receive a report of a serious adverse event with such dietary supplement.
FRNMFGREG
The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. It appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.
UNSAFE ADD
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to bear or contain an unsafe food additive within the meaning of section 409.
DIETARYLBL
The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it is a dietary supplement that appears to be misbranded within the meaning of Section 403(s)(2)(B) of the FD&C Act in that the label or labeling fails to identify the product by using the term "dietary supplement", which term may be modified with the name of such an ingredient.
Refusal History
| Date | Product | Violations | Division |
|---|---|---|---|
| 9/3/2024 | 54FEL99HERBALS & BOTANICALS (NOT TEAS), N.E.C. | 75UNAPPROVED | Division of Northeast Imports (DNEI) |
| 6/27/2024 | 54FGL99HERBALS & BOTANICALS (NOT TEAS), N.E.C. | 75UNAPPROVED | Division of Northeast Imports (DNEI) |
| 5/3/2024 | 54FBL99HERBALS & BOTANICALS (NOT TEAS), N.E.C. | 75UNAPPROVED | Division of Northeast Imports (DNEI) |
| 3/18/2024 | 54FBY99HERBALS & BOTANICALS (NOT TEAS), N.E.C. | 75UNAPPROVED | Division of Northeast Imports (DNEI) |
| 6/6/2023 | 54KCL08ALOE (HERBAL AND BOTANICAL (NOT TEAS) II (CONTINUED)) | 238UNSAFE ADD | Division of Southwest Imports (DSWI) |
| 4/29/2022 | 66YBL99EXHIBITS - OTHER DRUG RELATED ITEMS N.E.C. | 75UNAPPROVED | Division of Northeast Imports (DNEI) |
| 1/6/2022 | 66FBH99SUPPRESSANT N.E.C. | Division of Northeast Imports (DNEI) | |
| 1/6/2022 | 66FBL99SUPPRESSANT N.E.C. | 75UNAPPROVED | Division of Northeast Imports (DNEI) |
| 3/31/2021 | 54JGL08ALOE (HERBAL AND BOTANICAL TEAS II, (CONTINUED)) | Division of Northeast Imports (DNEI) | |
| 3/30/2021 | 54FGL99HERBALS & BOTANICALS (NOT TEAS), N.E.C. | 75UNAPPROVED | Division of Northeast Imports (DNEI) |
| 1/19/2021 | 54FGL99HERBALS & BOTANICALS (NOT TEAS), N.E.C. | 75UNAPPROVED | Division of Northeast Imports (DNEI) |
| 3/18/2020 | 54KYM08ALOE (HERBAL AND BOTANICAL (NOT TEAS) II (CONTINUED)) | Division of Southeast Imports (DSEI) | |
| 9/7/2018 | 54FCY99HERBALS & BOTANICALS (NOT TEAS), N.E.C. | 16DIRECTIONS | Division of Northeast Imports (DNEI) |
| 9/7/2018 | 54FCY99HERBALS & BOTANICALS (NOT TEAS), N.E.C. | 16DIRECTIONS | Division of Northeast Imports (DNEI) |
| 9/7/2018 | 54FCY99HERBALS & BOTANICALS (NOT TEAS), N.E.C. | 16DIRECTIONS | Division of Northeast Imports (DNEI) |
| 9/7/2018 | 54FCY99HERBALS & BOTANICALS (NOT TEAS), N.E.C. | 16DIRECTIONS | Division of Northeast Imports (DNEI) |
| 9/7/2018 | 54FCY99HERBALS & BOTANICALS (NOT TEAS), N.E.C. | 16DIRECTIONS | Division of Northeast Imports (DNEI) |
| 2/21/2018 | 66MBL99TRANQUILIZER N.E.C. | Division of Northeast Imports (DNEI) | |
| 1/13/2014 | 36CCT04HONEY | New York District Office (NYK-DO) | |
| 1/13/2014 | 66VBL99MISCELLANEOUS PATENT MEDICINES, ETC. | New York District Office (NYK-DO) | |
| 1/13/2014 | 66VBL99MISCELLANEOUS PATENT MEDICINES, ETC. | New York District Office (NYK-DO) | |
| 5/28/2013 | 66VCS99MISCELLANEOUS PATENT MEDICINES, ETC. | 16DIRECTIONS | Division of Northeast Imports (DNEI) |
| 5/28/2013 | 66VCS99MISCELLANEOUS PATENT MEDICINES, ETC. | 16DIRECTIONS | Division of Northeast Imports (DNEI) |
| 7/5/2012 | 54FBY99HERBALS & BOTANICALS (NOT TEAS), N.E.C. | 218LIST INGRE | New York District Office (NYK-DO) |
| 12/9/2009 | 66VPL99MISCELLANEOUS PATENT MEDICINES, ETC. | New York District Office (NYK-DO) | |
| 12/9/2009 | 66VPL99MISCELLANEOUS PATENT MEDICINES, ETC. | New York District Office (NYK-DO) | |
| 12/9/2009 | 66VPL99MISCELLANEOUS PATENT MEDICINES, ETC. | New York District Office (NYK-DO) | |
| 12/9/2009 | 66VPL99MISCELLANEOUS PATENT MEDICINES, ETC. | New York District Office (NYK-DO) | |
| 9/21/2005 | 54ACL90MULTIPLE VITAMINS (MVI-12 VITAMIN COMBO) (VITAMIN) | 473LABELING | New York District Office (NYK-DO) |
| 9/21/2005 | 54ACL90MULTIPLE VITAMINS (MVI-12 VITAMIN COMBO) (VITAMIN) | 473LABELING | New York District Office (NYK-DO) |
| 3/23/2005 | 66VDL99MISCELLANEOUS PATENT MEDICINES, ETC. | New York District Office (NYK-DO) | |
| 9/13/2002 | 66CBN99STOOL SOFTENER N.E.C. | 335LACKS N/C | Philadelphia District Office (PHI-DO) |
Frequently Asked Questions
What is Capital O2 Natural Health Company Ltd's FDA import refusal history?
Capital O2 Natural Health Company Ltd (FEI: 3013153905) has 32 FDA import refusal record(s) in our database, spanning from 9/13/2002 to 9/3/2024.
What is an FEI number?
FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Capital O2 Natural Health Company Ltd's FEI number is 3013153905.
What types of violations has Capital O2 Natural Health Company Ltd received?
Capital O2 Natural Health Company Ltd has been cited for 12 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.
Where does this information about Capital O2 Natural Health Company Ltd come from?
All FDA import refusal data for Capital O2 Natural Health Company Ltd is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.
Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.